Ascentage Pharma reported a 33% increase in first-half product sales as commercial adoption of its oncology portfolio continued expanding in China, including a substantial increase in hospital formulary coverage for olverembatinib.
Product sales increased 32.6% on a constant-currency basis to $41.6 million from $29.7 million in the first half of 2025.
Total revenue increased 29.3% on a constant-currency basis to $44.5 million from $32.6 million, meaning product sales accounted for the vast majority of Ascentage Pharma’s first-half revenue. Olverembatinib continued expanding its commercial reach.
The number of direct-to-patient pharmacies and hospitals where the treatment was on formulary increased 12% to 879 from 782.
Within that total, hospital formulary coverage increased 34% to 394 hospitals from 295 a year earlier.
Olverembatinib is a third-generation BCR-ABL1 inhibitor approved in China for certain patients with chronic myeloid leukemia, including patients with T315I mutations and patients resistant or intolerant to earlier-generation TKIs.
The drug is included on China’s National Reimbursement Drug List. Ascentage is also conducting registrational Phase III studies of olverembatinib in chronic myeloid leukemia, newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia and SDH-deficient gastrointestinal stromal tumors.
The company’s second commercial product, lisaftoclax, had reached 415 direct-to-patient pharmacies and hospitals by the end of June, including 60 hospitals. Ascentage is advancing the Bcl-2 inhibitor through four registrational Phase III programs.
Commercial and clinical expansion is driving substantially higher spending.
Selling and distribution expenses increased 64.3% on a constant-currency basis to $33.4 million, primarily because of increased marketing and promotion for lisaftoclax.
R&D spending increased 32% to $102.8 million, more than twice first-half revenue, as Ascentage accelerated its global clinical programs.
Ascentage reported a first-half loss of $120.4 million compared with $82.5 million a year earlier and ended June with $279.4 million in cash and bank balances.
KEY QUOTES:
“During the first half of 2026, we continued to execute on our key strategic priorities while expanding our global footprint.”
Dr. Dajun Yang, Chairman and Chief Executive Officer of Ascentage Pharma
